Key facts
- This page summarizes Peter Linde's Form 4 filing for Morphic Holding, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2021, 19:15.
Peter Linde - 01 Jun 2021 Form 4 Insider Report for Morphic Holding, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Jun 2021
- Net transaction value
- -$299,110
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2021, 19:15:39 UTC
- Next SEC filing
- 17 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Farrell as attorney-in-fact for Peter Linde
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter Linde filed Form 4 for Morphic Holding, Inc. on 03 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$299,110.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MORF
transaction
Common Stock
Sale
- Transaction value
- $231,100
- Shares
- -4,648
- Change %
- -44%
- Price
- $49.72
- Shares after
- 5,952
- Date
- 01 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
MORF
transaction
Common Stock
Sale
- Transaction value
- $68,010
- Shares
- -1,352
- Change %
- -23%
- Price
- $50.30
- Shares after
- 4,600
- Date
- 01 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.06 to $50.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.06 to $50.87 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.